vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and SITIME Corp (SITM). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $113.3M, roughly 1.7× SITIME Corp). SITIME Corp runs the higher net margin — 8.1% vs -14.6%, a 22.7% gap on every dollar of revenue. On growth, SITIME Corp posted the faster year-over-year revenue change (66.3% vs 65.0%). SITIME Corp produced more free cash flow last quarter ($13.0M vs $-18.7M). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 61.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
AXSM vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $113.3M |
| Net Profit | $-28.6M | $9.2M |
| Gross Margin | — | 56.4% |
| Operating Margin | -13.8% | 1.6% |
| Net Margin | -14.6% | 8.1% |
| Revenue YoY | 65.0% | 66.3% |
| Net Profit YoY | 61.9% | 148.7% |
| EPS (diluted) | $-0.55 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $113.3M | ||
| Q3 25 | $171.0M | $83.6M | ||
| Q2 25 | $150.0M | $69.5M | ||
| Q1 25 | $121.5M | $60.3M | ||
| Q4 24 | $118.8M | $68.1M | ||
| Q3 24 | $104.8M | $57.7M | ||
| Q2 24 | $87.2M | $43.9M | ||
| Q1 24 | $75.0M | $33.0M |
| Q4 25 | $-28.6M | $9.2M | ||
| Q3 25 | $-47.2M | $-8.0M | ||
| Q2 25 | $-48.0M | $-20.2M | ||
| Q1 25 | $-59.4M | $-23.9M | ||
| Q4 24 | $-74.9M | $-18.8M | ||
| Q3 24 | $-64.6M | $-19.3M | ||
| Q2 24 | $-79.3M | $-26.8M | ||
| Q1 24 | $-68.4M | $-28.7M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 51.9% | ||
| Q1 25 | — | 50.3% | ||
| Q4 24 | — | 52.6% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 49.1% | ||
| Q1 24 | — | 53.5% |
| Q4 25 | -13.8% | 1.6% | ||
| Q3 25 | -27.0% | -19.2% | ||
| Q2 25 | -24.5% | -35.4% | ||
| Q1 25 | -46.9% | -46.6% | ||
| Q4 24 | -61.1% | -33.8% | ||
| Q3 24 | -59.8% | -43.1% | ||
| Q2 24 | -89.5% | -73.7% | ||
| Q1 24 | -89.7% | -106.1% |
| Q4 25 | -14.6% | 8.1% | ||
| Q3 25 | -27.6% | -9.6% | ||
| Q2 25 | -32.0% | -29.0% | ||
| Q1 25 | -48.9% | -39.6% | ||
| Q4 24 | -63.1% | -27.6% | ||
| Q3 24 | -61.7% | -33.5% | ||
| Q2 24 | -91.0% | -61.0% | ||
| Q1 24 | -91.1% | -86.9% |
| Q4 25 | $-0.55 | $0.44 | ||
| Q3 25 | $-0.94 | $-0.31 | ||
| Q2 25 | $-0.97 | $-0.84 | ||
| Q1 25 | $-1.22 | $-1.01 | ||
| Q4 24 | $-1.54 | $-0.80 | ||
| Q3 24 | $-1.34 | $-0.83 | ||
| Q2 24 | $-1.67 | $-1.16 | ||
| Q1 24 | $-1.44 | $-1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.2B |
| Total Assets | $689.8M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.1B | ||
| Q2 25 | $73.1M | $1.1B | ||
| Q1 25 | $53.2M | $692.5M | ||
| Q4 24 | $57.0M | $699.7M | ||
| Q3 24 | $92.9M | $696.2M | ||
| Q2 24 | $102.9M | $692.5M | ||
| Q1 24 | $144.0M | $696.2M |
| Q4 25 | $689.8M | $1.3B | ||
| Q3 25 | $669.3M | $1.3B | ||
| Q2 25 | $639.8M | $1.3B | ||
| Q1 25 | $596.7M | $872.1M | ||
| Q4 24 | $568.5M | $885.0M | ||
| Q3 24 | $561.5M | $877.9M | ||
| Q2 24 | $548.2M | $878.6M | ||
| Q1 24 | $545.7M | $942.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $25.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $13.0M |
| FCF MarginFCF / Revenue | -9.6% | 11.5% |
| Capex IntensityCapex / Revenue | 0.0% | 10.9% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $35.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $25.4M | ||
| Q3 25 | $1.0M | $31.4M | ||
| Q2 25 | $-32.4M | $15.3M | ||
| Q1 25 | $-43.4M | $15.0M | ||
| Q4 24 | $-26.2M | $13.5M | ||
| Q3 24 | $-18.6M | $8.2M | ||
| Q2 24 | $-30.1M | $-181.0K | ||
| Q1 24 | $-53.5M | $1.7M |
| Q4 25 | $-18.7M | $13.0M | ||
| Q3 25 | $988.0K | $26.3M | ||
| Q2 25 | $-32.4M | $-2.9M | ||
| Q1 25 | $-43.7M | $-1.3M | ||
| Q4 24 | $-26.2M | $-2.4M | ||
| Q3 24 | $-18.7M | $-6.7M | ||
| Q2 24 | $-30.2M | $-2.7M | ||
| Q1 24 | $-53.6M | $-1.2M |
| Q4 25 | -9.6% | 11.5% | ||
| Q3 25 | 0.6% | 31.5% | ||
| Q2 25 | -21.6% | -4.2% | ||
| Q1 25 | -36.0% | -2.1% | ||
| Q4 24 | -22.1% | -3.5% | ||
| Q3 24 | -17.9% | -11.6% | ||
| Q2 24 | -34.6% | -6.3% | ||
| Q1 24 | -71.4% | -3.6% |
| Q4 25 | 0.0% | 10.9% | ||
| Q3 25 | 0.0% | 6.1% | ||
| Q2 25 | 0.0% | 26.2% | ||
| Q1 25 | 0.3% | 27.0% | ||
| Q4 24 | 0.0% | 23.3% | ||
| Q3 24 | 0.1% | 25.7% | ||
| Q2 24 | 0.1% | 5.8% | ||
| Q1 24 | 0.1% | 8.8% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
